弓健副教授)分享了2023年4月发表在Journal of Nuclear Medicine上的文章《Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study》。
[关键词] 镥-177标记前列腺特异性膜抗原放射性配体疗法;前列腺癌;临床实践;专家共识 [Abstract] 177Lu-labeled prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an innovative treatment approach that precisely ...
[4] 177Lu-PSMA 放射性配体疗法治疗前列腺癌的临床实践专家共识(2024年版). 中国癌症杂志, 2024, 34(07):702-714. [5] [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals, 2022, 15(10):1292. [6] 2023年诺华年报. [7]...
[Abstract]177Lu-labeled prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an innovative treatment approach that precisely delivers β radiation emitted by177Lu to prostate cancer cells, causing radiation da...
Evidence-based Medicine. The purpose of this consensus was to provide physicians with reference for clinical application in the practice of 177Lu-PSMA-RLT for the treatment of prostate cancer based on existing evidence and lay the foundation for the development of subsequent industry-related ...
, 西南医科大学附属医院核医学科,核医学与分子影像四川省重点实验室,泸州 646000 基金项目: 泸州市-西南医科大学核素精准诊疗研究项目(2016lzxnyd-g01) 详细信息 progress in radioligand therapy with 177 lu-psma for the treatment of metastatic castration-resistant prostate cancer yanhong zhao , yue chen , ...
[7] LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) , Abstract 5005, 2023 ASCO. [8] PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients...
Lu-177RADIOLIGAND THERAPYANDROGEN DEPRIVATIONSURVIVAL ANALYSISPLUS PREDNISONEANTIGENPurpose This study was set out to analyze the efficacy and safety of Lu-177-PSMA-617 (LuPSMA) treatment in metastatic castration-resistant prostate cancer (mCRPC) patients. Patients and Methods Progressive mCRPC patie...
[关键词] 前列腺特异性膜抗原;转移性去势抵抗性前列腺癌;177 镥;放射性配体治疗 DOI:10.13201/j.issn.1001-1420.2022.05.009 [中图分类号 ] R737.25 [文献标志码 ] A Applicationof177LuPSMAradioligandinthetreatmentofmetastatic castration-resistantprostatecancer WU Peng1 ZHANGJingliang1 LIYu1 ZHANG Mingru2 ...
目前,177Lu标记的前列腺特异性膜抗原靶向治疗是最有希望的新疗法之一,有望成为前列腺癌的标准治疗方案之一,该疗法安全、有效,可延长患者的总体生存期。 关键词: 前列腺特异膜抗原 / 前列腺肿瘤 / 分子靶向治疗 / 转移性去势抵抗性前列腺癌 / 177Lu Abstract: Prostate cancer is one of the most ...